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NeovascularizationRecent cell-based therapy approaches have employed both nanotechnologies and other biomedical technologies
to enhance their therapeutic potential. A combined strategy using therapeutic stem/progenitor cells and
angiogenic proteins is attractive for the treatment of vascular disease. In this study, we developed an injectable
multifunctionalmicro-sizedgel system (microgel), composed of arginine–glycine–aspartic acid (RGD)-conjugated
alginate, for the delivery of both cells and growth factors in vivo. The microgels encapsulated with outgrowth
endothelial cells (OECs) and growth factors (vascular endothelial growth factor, VEGF, and hepatocyte growth
factor, HGF) were formed via electrospraying. Cells encapsulated within the microgel exhibited a time-
dependent proliferation with enhanced cell viability, and the size-controlled microgels resulted in
sustained release of growth factors for enhanced new vessel formation by tube formation and rat aorta
sprouting in vitro. Increased angiogenesis was also estimated inmice treated with RGD-microgel containing
OECs and growth factors. Furthermore, injection of the multifunctional microgel into a hindlimb ischemia
model improved blood ﬂow perfusion and increased the capillary density by histological analysis. Compared
with hydrogel system, injectable microgel system was shown to be superior with no toxicity. Overall, our
injectable multifunctional microgel system can be attributed to deliver potential therapeutic agents/cells
for the treatment of vascular diseases.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Over the past few decades, cell-based therapies have been evaluated
with the aim of developing a delivery system for therapeutic cells.
This method can increase the therapeutic potency and overcome the
low survival of cells at the disease site to enhance revascularization
and vessel regeneration. The term ‘therapeutic angiogenesis’ refers to
the induction of collateral blood vessel development and capillary
regeneration through various mechanisms of action using angiogenic
growth factors and stem cells [1,2].
For therapeutic neovascularization via vasculogenesis or angiogene-
sis, endothelial progenitor cells (EPCs) have been considered to inducemistry, College of Veterinary
anak-gu, Seoul, South Korea.
. This is an open access article undercollateral blood vessel development for myocardial and limb ischemia
since their introduction in the late 1990s [3]. EPCs are classiﬁed into
two types of cells: early EPCs and late EPCs. Both cells show stem cell-
like potency. Among them, late EPCs, also called outgrowth endothelial
progenitor cells (OECs), are known to have more endothelial cell-like
characteristics compared to early EPCs, and they release several
angiogenic cytokines. Thus, OECs have the ability to induce the
therapeutic effects for the treatment of vascular disease. However,
the therapeutic cells used in most cell therapy approaches exhibit
several problematic factors when injected into the disease site.
Several of these hurdles include the accumulation of the cells in the
lungs and immobilization at the disease site when systemically
injected, in addition to low cell survival and tissue damage from an
injection bolus when locally injected [4]. To improve therapeutic
angiogenesis using OECs, better strategies are required.
Other approaches for the induction of neovascularization via
angiogenesis and arteriogenesis are to use therapeutic angiogenic
growth factors, such as vascular endothelial growth factor (VEGF) andthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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roles in angiogenesis and tissue regeneration and are key regulators in
new blood vessel formation [5,6]. Recently, combination therapies of
angiogenic factors, such as VEGF and basic ﬁbroblast growth factor
(bFGF), or platelet-derived growth factor-BB (PDGF-BB) and bFGF,
were shown to synergistically induce angiogenesis and the formation
of long-lasting, functionally stable vessels [7,8]. However, protein
delivery is another issue that needs to be overcome, as a major
disadvantage is their rapid degradation rate, which results in a short
half-life and, consequently, low therapeutic efﬁcacy.
Recent studies focused on cell therapy have been exploited by
fusing this type of research with the ﬁeld of nanotechnology to
enhance their therapeutic potency and cell viability [9]. Among
the combined strategies with nanotechnology, cell encapsulation
technologies are an optimal approach to induce a concentrated
therapy at a local site, and are necessary to improve the therapeutic
efﬁcacy of cell-based materials in vivo. Various matrices, including
avidin microspheres, antibody microgels, and poly (D,L-lactic-co-
glycolic acid) (PLGA), have been used to improve the stability and vi-
ability of therapeutic cells at a target site [10,11]. These matrices
have also shown a favorable protective effect of the cells against a
host immune response, which canmaintain their prolonged stability.
Among them, alginate, which is a naturally occurring anionic polymer,
is formed into a gel by cross-linking in the presence of divalent ions.
In addition, alginate is a biomaterial capable of applying to biomedical
science due to high biocompatibility and is often used to generate
hydrogel for the delivery of drugs, proteins, and cells [12–14].
Arginine–glycine–aspartic acid (RGD) conjugation and oxidization can
also be applied to the alginate structure to improve cell immobilization,
potency, and degradability [13].
In this study, we developed injectable RGD-conjugated microgels
with an average diameter of 150 μm and that encaspsulated both
OECs and growth factors, including VEGF and HGF, to induce enhanced
neovascularization for hindlimb ischemia.
2. Materials and methods
2.1. Cell cultures
Human outgrowth endothelial cells (OECs), isolated from human
umbilical cord blood, were kindly provided by Dr. Sang-Mo Kwon
from Pusan National University in South Korea. The OECs were
maintained in endothelial cell basal medium-2 (EBM-2; Lonza,
Walkersville, MD) supplemented with EGM™-2 singleQuots® (Lonza)
except ascorbic acid at 37 °C and 5% CO2. HEK293, a human embry-
onic kidney cell line, was purchased from American Type Culture
Collection (ATCC, Manassas, VA). HEK293 were cultured in
Dulbecco's Modiﬁed Eagle's Medium (DMEM; Gibco-BRL, Grand Is-
land, NY) supplemented with 10% fetal bovine serum (FBS; Gibco-
BRL) and penicillin/streptomycin (Gibco-BRL).
2.2. RGD-alginate synthesis
The arginine–glycine–aspartic acid (RGD)-conjugated alginate
was synthesized as previously described [15]. Brieﬂy, a 1.0 wt.%
alginate solution was prepared by dissolving 1.0 g of sodium alginate
(FMC Biopolymer, Philadelphia, PA) in 100 mL of 0.1 M 2-(N-
morpholino) ethanesulfonic acid (MES) buffered saline (Thermo
Fisher Scientiﬁc, Rockford, IL). Under constant stirring, 18.1 mg of
N-hydroxysulfosuccinimide (sulfo-NHS; Sigma Aldrich, St. Louis, MO)
and 16.0 mg of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
(EDC; Sigma Aldrich) were added to the alginate solution. After
5 min, 9.6 mg of YRGDS peptide was added to the solution. The
molar ratio of NHS: EDC: RGD = 3:3:1. The peptide was prepared
by solid phase synthesis. The mixture was stirred for another
24 h to complete the reaction. The RGD-alginate was puriﬁed bydialysis against distilled water for 2 days, ﬁltered, and lyophilized
for storage.
2.3. Microgel fabrication and cell encapsulation
An electrospraying device, including a high-voltage supply, a syringe
pump, a stainless-steel nozzle, and a 28-gauge syringe needle,
was purchased from NanoNC (NNC-ESP 200, Seoul, South Korea).
OECs (2 × 106/mL) were suspended in the RGD-alginate solution
(1 wt.%) and transferred to a syringe, which was then loaded into the
syringe pump. In addition, VEGF (R&D Systems, Inc., Minneapolis, MN)
and HGF (PeproTech, Rocky Hill, NJ) were added to the cell/alginate
solution for a ﬁnal concentration of 0.5 μg/mL. The mixture was
electrosprayed into a 100 mM calcium chloride (CaCl2) solution at var-
ious ﬂow rates (2–5 mL/h) and at an applied voltage of 10 kV. After
microgel formation, unencapsulated cells and growth factors, non-
gelated alginate, and the remaining CaCl2 solution were removed
using a Falcon® 70 μm Cell Strainer (BD, Franklin Lakes, NJ), and the
microgels were washed with HEPES. Acellular microgels were synthe-
sized as a control. The sizes and morphologies of the resulting RGD-
alginate microgels encapsulated with OECs were observed using an
optical or ﬂuorescence microscope (Olympus CKX41, Olympus Corpo-
ration, Tokyo, Japan and JuLITM FL, NanoEnTek, Seoul, South Korea).
To test whether the cells encapsulated into the microgels were
viable and actually proliferated, the 293T cells were transfected using
lipofectamine to deliver 0.5 μg of green ﬂuorescence protein (GFP)-
expressing plasmid. At 24 h post-transfection, the cell suspension
mixed with the RGD-alginate was electrosprayed, as described above.
To assess the proliferation of the cells in the microgel, the medium
was exchanged with fresh medium every three days. The viability
of the encapsulated GFP-expressing cells and time-dependent cell
proliferation were visualized using a JuLI microscope (NanoEnTek).
2.4. Sustained release of BSA-FITC from the microgels
The release proﬁle of FITC-conjugated bovine serum albumin
(BSA-FITC, 66 kDa; Sigma-Aldrich) from the microgels was measured
using ﬂuorescence spectroscopy (λex = 488 nm, λem = 522 nm)
using Inﬁnite® 200 PRO TECAN Ltd. The microgel (1% w/v alginate,
100 μm/ml BSA-FITC) samples were incubated in PBS at 37 °C for up
to 7 days. Supernatants at the desired time points (0, 1, 3, 6, 12 h
and 1–7 days) was collected and analyzed in triplicate. Relative
ﬂuorescence intensity (arbitrary unit) values were converted into the
actual weight of BSA-FITC released by correlationwith a standard curve.
2.5. Tube formation and ex vivo aorta sprouting assay
Tube formation was assessed by culturing human umbilical
vein endothelial cells (HUVECs) on BD Matrigel (BD Biosciences,
San Jose, CA). HUVECs were seeded onto a layer of Matrigel within
24-well plates at a density of 5 × 104 cells per well. HUVEC cells
were then exposed to conditioned media, which was collected from
the multifunctional microgels, to form tube-like structures for 35 h.
The conditioned medium was created by incubating the multifunc-
tional microgels (containing 2 × 106/mL OECs cell density, 0.5 μg
growth factors) in EGM-2 medium for 96 h. EGM-2 media was used
as a control. Tube formation was analyzed by quantifying the
number of branches per high-powered ﬁeld. Aortic rings (1–2 mm
segments) were isolated from Sprague–Dawley rats (6 weeks old)
and placed in the lower part of 24-Transwell plate (Falcon) coated
with 200 μl of Matrigel. Then, other components, such as media
only, microgels only, growth factors (VEGF/HGF) only, OECs only,
microgels with OECs, and microgels with OECs and growth factors
(0.5 μg VEGF and HGF, respectively) were added to the Transwell
inserts with a 8 μm microporous membrane. Co-cultures were
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using a JuLI microscope (NanoEnTek).
2.6. Blood vessel induction plug assay
The fabricated RGD-microgels, containing both OECs and growth
factors, were injected subcutaneously in the midventral abdominal
region of 7–8 week-old mice and allowed to solidify. After 1 week,
the mice were anesthetized, the skin above the RGD-alginate plug
was gently shaved, and any angiogenesis that was observed was
photographed.
To compare the superiority between our injectable microgel
system and a hydrogel system, PBS and the multifunctional RGD-
microgels, containing OECs and growth factors were injected sub-
cutaneously in the midventral abdominal region of 7–8 week-old
mice. An RGD-hydrogel containing OECs and growth factors was
also implanted at the same site. After 1 week post-injection,
the skin of the anesthetized mice was cut at the abdomen and
photographed.
2.7. Hindlimb ischemia model and in vivo microgel injection
After a skin incision of anesthetized female BALB/c mice
at 5 weeks of age (16–20 g body weight; OrientBio, Gyeonggi
province, Republic of Korea), the femoral artery and its branches
were ligated with 4–0 nylon (AILEE, Pusan, South Korea). Then,
the external iliac artery and all of the above arteries were ligated.
The femoral artery was excised from its proximal origin as previous-
ly described [16]. One week after the femoral artery dissection sur-
gery, mice were randomly assigned to one of ﬁve experimental
groups (n = 6 for each group). No treatment was given to the con-
trol group. Induced hindlimb ischemia of the mice was treated by a
single intramuscular injection into three or four gracilis muscles at
the ischemic limbs in the medial thigh with either PBS, control
microgels, OECs (2 × 107 cells in RGD-alginate 1 mL per mouse),
microgels with OECs only, and microgels with OECs and VEGF/HGF
(0.5 μg per mouse, respectively). The concentration of each of
the starting materials was the same. To ensure success, complete oc-
clusion of overall blood perfusion to the hindlimb was evaluated
using a Laser-Doppler Flowmeter (Moor LDI, Moor Instruments
Ltd., Devon, UK) before occlusion and after occlusion, and then
every week for 4 weeks after the speciﬁc treatment. The data
were analyzed using moorLDI™-PC-software. All animal studies
were performed according to the Seoul National University Animal
Care Committee guidelines after acquiring permission from the
committee (Protocol #SNU-130214-2-1).
2.8. Immunohistochemistry
Tissues were harvested, ﬁxed in formalin-free IHC zinc ﬁxative
formalin-free (BD Biosciences PharMingen, San Diego, CA), embedded
in parafﬁn, and cut into 5-μm sections (Leica, Buffalo Grove, IL).
Representative sections were immunostained with von Willibrand fac-
tor (vWF) (Merck Millipore, Billerica, MA). Furthermore, sections were
stained with hematoxylin and eosin (H&E). Blood vessels were counted
as described previously [17,18]. The data are presented asmean± s.e. of
three hindlimbs per group.
2.9. Statistical analysis
Data are expressed as the mean ± standard error of the mean.
Statistical comparisons were made using StatView software (Abacus
Concepts, Inc., Berkeley, CA) and a paired t-test was used for com-
paring the baseline and treated groups post injection. Differences
were considered statistically signiﬁcant when P values were less
than 0.05.3. Results
3.1. Microgel encapsulation of OECs by electrospraying
To assess the optimum conditions for microgel formation with the
desired morphology, size, and cell encapsulation, the 1% RGD-alginate
solution containing OECs was electrosprayed under different applied
ﬂow rates (2, 3, 4, and 5 mL/h) at a constant voltage (10 kV). Fig. 1
depicts the average size of the resulting RGD-alginate microgels,
whichwas approximately 120–150 μm in diameter at the lower applied
ﬂow rates (2 and 3 mL/h) and tended to increasewith an increase in the
applied ﬂow rate. Moreover, the morphologies and sizes of the formed
microgels over 4 mL/h were not clear circular form and heterogeneous.
Therefore, the applied ﬂow rate was maintained at 3 mL/h for the
remainder of the experiments. Under these conditions (100 mM
CaCl2, 3 mL/h ﬂow rate, 1% RGD-alginate, and 10 kV), the RGD-
alginate microgel without cells were measured to be a similar size
(approximately 121 μm in diameter) compared to the RGD-alginate
microgels containing OECs (Fig. 1). These results suggest that a
lower ﬂow rate was favorable for obtaining RGD-alginate microgels
with a spherical morphology.
3.2. Cell viability and proliferation of the encapsulated cells in the
RGD-alginate microgels
To access whether the cells encapsulated in the microgels actually
proliferated, RGD-alginate microgels containing 293T cells or OECs
were formed using the electrospraying method described above. The
293T cells encapsulated within the RGD-alginate microgels were
maintained in DMEM with 10% FBS for 21 days, with the medium
being changed every 3 or 4 days. The cells encapsulated within the
microgels were observed using a phase contrast image at days 0, 3, 7,
10, 14, and 21. As shown by the black spots in Fig. 2, the amount of
cells encapsulated within the microgels was initially relatively small
and then the cells gradually proliferated and the amount of cells in-
creased over time. The cell viability of the GFP-plasmid transfected
cells that were encapsulated within the microgels was directly con-
ﬁrmed by the expression of GFP within the microgels after fabrication,
indicating that the encapsulated cells were not affected by the exposure
to a high voltage during the course of electrospraying (Supplementary
Figs. 1 and 2). The proliferation of the OECs encapsulated within the
microgels was also estimated using alamar blue assay. OECs in the
microgels proliferated well, in a time-dependent manner. Increased
cell proliferation was elicited by the RGD-microgel when compared
to a non-modiﬁed alginate microgel (Supplementary Fig. 3). Taken
together, the cells in the microgels showed an increase in cell numbers
that depended on time. These results indicate that the cells encapsulated
into the RGD-alginate microgel can safely grow up in the microgel.
3.3. Protein release proﬁle from the RGD-alginate microgels
To assess the release proﬁle of proteins encapsulated within the
RGD-alginate microgels, FITC-conjugated BSA was encapsulated within
the RGD-alginate microgels. BSA-FITC was used as a model for in vitro
protein release from the alginate microgel system. The release of
FITC-BSA from the microgels was examined by the detection of FITC
conjugated to BSA (Fig. 3).
In Fig. 3(A), the amount of BSA-FITC released at day 0 in the samples
of 50 mM CaCl2 were substantially higher than the samples of 100 mM.
Twenty micrograms of BSA-FITC was detected in 50 mM CaCl2
condition, while less than 10 μg was detected in 100 mM condition.
This result indicates that BSA-FITC was not fully encapsulated in
50mMCaCl2 condition and that therapeutic proteins for in vivo delivery
should be encapsulated in 100 mM CaCl2 condition to avoid the
unwanted loss. The alginate concentration was also changed. As
the concentration increases, encapsulated BSA-FITC showed more
X 115 X 225
500 m
A B
C D
Fig. 1. Characterization of the RGD-alginate microgels, depending on the alginate ﬂow rate. Cells were encapsulated under various ﬂow rate conditions. The following conditions
were used to form the microgels: 1% RGD-alginate solution, 100 mM CaCl2, 10 kV voltage. (A) 2 mL/h ﬂow rate, (B) 3 mL/h ﬂow rate, (C) 4 mL/h ﬂow rate, and (D) 5 mL/h ﬂow
rate. After electrospraying, the resulting RGD-alginate microgel- encapsulated cells were photographed using a phase contrast JuLi microscope. The length of the block on the
scale bar is 500 μm.
X 225
A
(A) Immediately post-microgel formation
(B) 3 days post-microgel formation
(C) 7 days post-microgel formation
(D) 10 days post-microgel formation
(E) 14 days post-microgel formation
(F) 21 days post-microgel formation
B C
D E F
Fig. 2. Time-course of cell proliferation encapsulated in the RGD-alginate microgels. 293T cells expressing GFP were encapsulated into the RGD-alginate microgels and then the microgel
encapsulated cells were imaged in a time-dependent manner. Cells in themicrogel were observed as black spots due to the phase-contrast microscope. Over a period of time, the number
of black spots increased, forming aggregates in the microgel.
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Fig. 3. BSA-FITC release proﬁle from the RGD-alginate microgels, over time. The sustained
release of BSA-FITC from microgels was measured using ﬂuorescence spectroscopy. After
analyzing samples in triplicates, the relative ﬂuorescence intensity (arbitrary unit) values
were converted into the actual weight of BSA-FITC released. Data represent the means
and standard errors of the triplicate experiments. (A) Release proﬁle according to the
concentration of alginate and CaCl2, (B) Late time release proﬁle at the optimal
microgle condition.
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alginate 0.5%/100 mM CaCl2 condition, while over 10 days for the
samples in both alginate 1.0%/100 mM CaCl2 condition and alginate
2.0%/100 mM CaCl2 condition. These two conditions for microgels
both showed a similar sustained-release proﬁle of BSA-FITC. These
results suggest that electrospun microgel system in appropriate
conditions might be applicable to sustained release of angiogenic
growth factors for in vivo delivery. We then chose the condition of
microgels as alginate 1.0%/100 mM CaCl2 condition. Because the
average 8.3 μg of BSA-FITC was remained in microgels of alginate
2.0%/100 mM CaCl2 condition after 10 days, nearly 100% of BSA-
FITC was released in microgels of alginate 1.0%/100 mM CaCl2
condition. In the assessment of late time release proﬁle at the optimal
condition, an accumulated release of 48% of BSA-FITC was observed
during the ﬁrst day. The remaining 51.7% of BSA-FITC demonstrated a
slow release proﬁle over 10 days, as observed in the release proﬁle
graph of Fig. 3(B). It can be observed that after 5 days, a nearly linear
cumulative release curve was observed. These results indicate that the
RGD-alginate microgel system, which was formed by electrospraying,
might be able to induce a sustained release of angiogenic growth factors
for in vivo delivery.
3.4. The effects of OECs and growth factors encapsulated within
RGD-alginate microgels on endothelial cells
We next assessed the functional effects of the RGD-alginate
microgels containing OECs and growth factors on capillary tube forma-
tion in vitro and vessel induction ability ex vivo. Conditionedmediawereobtained from PBS, RGD-alginate microgels only, OECs only, RGD-
alginate microgels with OECs, or RGD-alginate microgels with OECs
and growth factors. HUVEC cells seeded onto Matrigel-coated plates
were incubated in the presence of each of the conditioned media.
As shown in Fig. 4, the conditioned media from PBS and the
microgels only showed minimal tube formation of HUVECs. On the
other hand, HUVECs incubated with conditioned media from RGD-
alginate microgels with OECs and from RGD-alginate microgels
with OECs and growth factors resulted in the formation of robust,
interconnected and elongated tubular structures, which were
organized with a much larger number of cells. Similarly, the HUVECs
formed tube-like structures when incubated with the medium from
OECs only.
The microvessel induction ability of the RGD-alginate microgel
system containing OECs and growth factors was then assessed by the
sprouting of rat aortic rings. As shown in Fig. 5, the microvessel sprouts
from the aortic ring displayed markedly different morphologies based
on the treatment group. A large number of microvessel endothelial
networks and branches sprouting from the aortic ring were observed
in the group treated with the RGD-alginate microgels containing OECs,
and RGD-alginate microgels containing OECs and growth factors. The
type of aortic sprouting microvessels and the extent of the capillary
networkwere examined in the RGD-alginatemicrogel group containing
OECs and growth factors. In particular, modest tube formation was
observed in HUVECs treated with the conditioned media obtained
from growth factors only. OEC only showed intermediate tube forma-
tion between growth factors only and media only. In contrast, neither
media only nor the microgels only group had an increased effect on
microvessels sprouting from the aortic rings. These data demonstrate
the ability for the potent induction of angiogenesis by OECs and growth
factors within the RGD-alginate microgels.
3.5. Increased neovascularization by OECs and growth factors encapsulated
within the RGD-alginate microgels in mouse skin
We next assessed whether the RGD-alginate microgels containing
OECs and growth factors can induce enhanced neovascularization
in vivo. PBS, RGD-alginate microgels only, OECs only, RGD-alginate
microgels with OECs, and RGD-alginate microgels with OECs and
VEGF/HGF growth factors were injected subcutaneously, which ulti-
mately solidiﬁed to from a plug. Fig. 6 shows that the RGD-alginate
microgels containing OECs and growth factors, induced enhanced
neovascularization as compared to the other groups. The number of
blood vessels and capillaries formed by this group was enhanced
when compared to the groups with microgels only and OECs only.
Additionally, OECs induced a larger number of blood vessels when
encapsulated within the microgels along with growth factors.
These results also demonstrate that the RGD-alginate microgels con-
taining OECs and growth factors are capable of stimulating enhanced
neovasculogenesis.
3.6. Blood ﬂow perfusion of hindlimb ischemia-induced mice
To evaluate the therapeutic potential of the RGD-alginate microgels
containing OECs and growth factors, mice were induced with hindlimb
ischemia, as described in theMaterials andmethods section. Blood ﬂow
of the ischemic limb versus the normal limb was measured before
and after surgery using a Laser Doppler imaging system. At one week
after the induction of ischemia, mice were intramuscularly treated
with PBS, RGD-alginate microgels only, growth factors (VEGF/HGF)
only, OECs only, RGD-alginate microgels with OECs, and RGD-alginate
microgels with OECs and growth factors. The ﬂow recovery in the
murine ischemic hindlimb was sequentially assessed as the ratio of
ischemic to normal leg perfusion in the same animal during the time
course of 1 to 4 weeks.
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Fig. 4. Enhanced tube formation based on paracrine effects from OECs and growth factors encapsulated in RGD-alginate microgels. Conditioned media, harvested from PBS, RGD-alginate
microgels only, OECs only, RGD-alginate microgels with OECs, and RGD-alginate microgels with OECs and growth factors, was used to treat HUVECs seeded on matrigel. At 35 h post
treatment, representative images were taken using a JuLI microscope. (A) Images depicting tube formation, (B) The tube area within microscope ﬁeld.
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ﬂow before (pre-ischemia) the operation, a precipitous reduction in
ﬂow for the ischemic limb versus the normal limb was initially shown
after (post-ischemia) the operation for ischemia induction. After the
treatment, a recovery of blood ﬂow perfusion was mainly observed
in three groups: OECs only, RGD-alginate microgels with OECs, and
RGD-alginate microgels with OECs and growth factors. Mice treated
with growth factors only showed intermediate positive effect in
only early stage and then gradually decreased. The rest of the groups
(PBS and RGD-alginate microgels only) demonstrated a complete loss
of blood ﬂow to the hind limb, resulting in extreme necrosis.
Among the groups that demonstrated an effective recovery, in the
case of the OECs-treated mice, the therapeutic perfusion showed a re-
covery of minor regional blood ﬂow. On the other hand, administration
of the RGD-alginate microgels with OECs or RGD-alginate microgels
with OECs and VEGF/HGF growth factors elicited a greater markedﬂow recovery than the other groups. The quantiﬁcation results of
blood ﬂow perfusion showed a similar pattern as the laser Doppler
image depicted (Fig. 7B). Encapsulation of OECs and OECs with
VEGF/HGF growth factors in the RGD-alginate microgels led to a
markedly superior perfusion recovery, indicating that OECs encapsulat-
ed in the RGD-alginate microgels can enhance the therapeutic potential
for the treatment of limb ischemia.
3.7. Vessel formation and capillary density of RGD-alginate microgels
containing OECs and growth factors via immunohistochemistry
To assess whether new vessels were formed at the microgel-
injected site, vWF IHCwas carried out in the extracted thighmuscles.
A histological assessment was shown in Fig. 7C, depicting enhanced
angiogenesis and collateral growth. Tissue sections of the mice
limbs treated with OECs that were stained with vWF showed only
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7P.-H. Kim et al. / Journal of Controlled Release 187 (2014) 1–13modest vessel formation in the femoral collaterals of the muscle.
Limbs treated with only PBS or microgels demonstrated low or no
capillary formation in the muscle. In contrast, enhancement in
femoral collaterals was observed in the mice treated with the
microgels containing OECs and the microgels containing OECs and
growth factors. Capillary density measurement (Fig. 7D) using the
vWF immunostaining showed a similar tendency as in Fig. 7C. A
treatment with the microgels containing OECs and the microgels
containing OECs plus growth factors led to the formation of capillary
vessels with larger diameters. These results demonstrating the
presence of newly formed capillaries in the sectioned limb plugs suggest
that our microgel delivery system containing both OECs and growth
factors stimulate capillary vessel formation at the ischemic site.
3.8. In vivo assessment of the injectable RGD-alginate microgels compared
with a hydrogel system
To evaluate the biocompatibility and safety of our injectable system
comparedwith a hydrogel system, the RGD-alginatemicrogels contain-
ing OECs and growth factors were subcutaneously injected in the mice.The RGD-alginate hydrogels containing OECs and growth factors were
also transplanted under the skin using a surgical procedure. After
7 days, the mice were anesthetized and then skin near the treated site
was incised and photographed. Only one of three mice treated with
the injectable microgel system showed a mild scar, but the remainder
of the mice were normal (Fig. 8A). Similar to the results shown in
Fig. 6, increased blood vessel and capillary formation was observed in
mice treated with the injectable RGD-microgels. In contrast, the hydro-
gel system needed to be implanted via surgery due to the difﬁculty of
injectability. The hydrogel implant site exhibited a large white scar
and rigid ﬁbrous tissue (Fig. 8B). Blood vessel and capillary formation
was observed around the ﬁbrous tissue. In addition, seven of the ten
mice that were transplanted with the hydrogel died after 3–4 days of
implantation. These results suggest that our injectable microgel system
is safer and more biocompatible compared with the hydrogel system.
4. Discussion
Therapeutic neovascularization induces the regeneration of vascular
structures with a signiﬁcant increase in capillary numbers and blood
PBS OECs onlyMicrogel only
Mocrogel with OECs Microgel with OECs+Growh factors
Fig. 6. In vivo enhancement of angiogenesis using the combination of OECs and growth factors encapsulated within RGD-alginate microgels. PBS, RGD-alginate microgels only, OECs only,
RGD-alginate microgels with OECs, and RGD-alginate microgels with OECs and growth factors were subcutaneously injected into mice. At 1 week post-injection, the skin of themice was
incised, and then the blood vessels that were formed in the subcutaneous tissuewere imaged and compared. n=3 for each experimental condition. The black arrow depicts the injection
site for each of the treatment groups.
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growth by angiogenesis, arteriogenesis, and vasculogenesis was per-
formed based on angiogenic growth factors, stem cells, or endothelial
progenitor cells.
A variety of cell populations, including cardiac stem cells, natural
killer cells, bone marrow cells, dendritic cells, and endothelial pro-
genitor cells (EPCs), have been investigated in clinical revasculariza-
tion trials [19]. With respect to stem cell-based therapies, there is no
doubt that this method is a very promising tool to treat various dis-
eases, including cancer. This is, in part, due to the high therapeutic
multipotency and the capacity to secret trophic factors that contrib-
utes to repair via the promotion of vascularization and the inhibition
of cell death. In recent studies, endothelial progenitor cell-based
therapies have moved into the limelight as a treatment for vascular
disease such as limb ischemia [20].
However, cell-based therapies and angiogenic protein delivery
methods demonstrate several shortcomings for the use in clinical
application. The major limitation of protein delivery is a short half-life
by protein–protein interaction and host immune response as well as
proteolytic degradation. Thus, other approaches involving protein
delivery needs to be investigated, such as the combinationwith nonviral
system elements [21]. Cell-based delivery system not only induces en-
trapment of injected stem cells into the lungs, but also tissue damage
from the injection bolus and low cell survival at the injected site [22,23].
To overcome these disadvantages, a combinatorial approach using
suitable biomaterials to take advantage of the interplay with non-viral
systems is necessary to improve the therapeutic efﬁcacy of cell-based
therapies in vivo. Therefore, in this study we proposed and demonstrat-
ed a cell-based therapy that usedbiocompatible RGD-alginatemicrogels
to encapsulate cells and proteins to induce neovascularization. Out-
growth endothelial cells (also called late endothelial progenitor cells),
which are well-known to have endothelial-like characteristics, were
used in combination with VEGF and HGF growth factors, which areknown to play a central role in angiogenesis and tissue regeneration
and induce paracrine effects, attempt to create new blood vessel.
In the present study, we generated RGD-alginatemicrogels, in which
OECs and growth factors were encapsulated using an electrospraying
method. Fig. 1 reveals that the growth factors and OECs were well en-
capsulated into the RGD-alginatemicrogels. The RGD-alginatemicrogels
containing the OECs had a variety of sizes, based on the condition of
microgel formation. A microgel size of 120 to 150 μmwas determined
to be optimal when used as a deliverymethod to target certain diseases,
as the limit of oxygen diffusion in situ is approximately 100 to 200 μm.
Cells that exceed this distance from a capillary vessel become anoxic
(as determined by infrared spectroscopy of tumors in transparent skin
chambers in mice) [24]. Thus, we determined the microgel conditions,
which are shown in Fig. 1B, by considering the survival of cells encapsu-
lated within the microgels in relation with a view for the role of blood
vessels proposed by Judah Folkman and co-workers.
To improve cell-based therapies, the cell delivery materials are
one of the major factors contributing to cell survival. Usually, the cell
encapsulation strategy is based on the immobilization of cells within a
semipermeable membrane, in which the encapsulated cells can be
protected from both mechanical stress and, in a part, the host immune
attack [25]. In addition, cell encapsulation within biocompatible
materials that are capable of bidirectional diffusion of nutrients, oxygen
and waste would allow for enhanced cell function and cell survival.
An injectable matrix that still provides a microenvironment for cells
would be beneﬁcial to be employed for local therapeutics. Increased
cell proliferation in a time dependent manner, which is shown
in Fig. 2, suggests that the RGD-alginate microgels formed by
electrospraying were able to overcome low cell survival at the
injected site, indicating that the membrane is semi-permeable and
allows for the release of the secretory growth factors from the encap-
sulated cells. Altogether, our encapsulation systemmay demonstrate
an increased therapeutic effect by reducing the immune response.
9P.-H. Kim et al. / Journal of Controlled Release 187 (2014) 1–13Consequently, as shown in Fig. 2, our semi-permeable RGD-alginate
microgels demonstrated sustained release of the encapsulated BSA-
FITC, without an early burst release, as shown in Fig. 3. Because most
angiogenic proteins have a short half-life in vivo as well as potential
toxicity and risk of carcinogenic activity, direct injection of the protein
at the target site is not appropriate [26]. Therefore, a controlled and
localized delivery system of angiogenic proteins, such as our injectable
RGD-alginate microgel system, would be appropriate for therapeutic1 week 2 we
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10 P.-H. Kim et al. / Journal of Controlled Release 187 (2014) 1–13utilization of progenitor cell highly depends on the mode of delivery
and control over cell fate due to low cell survival at the transplanted
or injected site. In addition, OECs (late EPCs) release some angiogen-
ic cytokines, including VEGF, interleukin-8 (IL-8), and stem cell-
derived factor-1 (SDF-1), although it does not express as high
enough compared to early EPCs [28], which results in the induction
of enhanced vasculogenesis. Moreover, the molecular processes
leading to angiogenesis and arteriogenesis involve mediators such
as nitric oxide, VEGF, bFGF, HGF, angiopoietin, and others. These
factors lead to angiogenesis and arteriogenesis via stimulation
of endothelial cell sprouting from preexisting blood vessel or
proliferation/migration of endothelial cell residing within remodel-
ing collaterals [2]. Therefore, the use of these factors allows for
the induction of improved blood vessel formation by promoting
neovascularization.
Based on the facts described above, we have demonstrated en-
hanced neovascularization using RGD-alginate microgels containing
OECs and growth factors. This was accomplished using several in vitro
and in vivo studies, including observation of tube formation, an aorta
sprouting assay, and a subcutaneous injection assay (Figs. 4, 5, and 6).
These improved results also likely prove that there are mild conditions
within the microgel, which could minimize the denaturation of growth
factors as well as protect the cells from physical damage and increase
the stability of the cells (due to the RGD structure). For examples of
our experiment, growth factors only group used in aorta sprouting
assay showed positive effect, but not in hindlimb ischemia study
possibly because of the proteolytic degradation and short activity. It
has also been shown that the combination of OECs and growth factors
into the RGD-alginate microgels can play an import role in determining
the increase in capillary density and collateral development in ischemic
hind limb tissues, as shown in Fig. 7. This indicates that delivery of OECs
and growth factors using the injectable microgel system induces en-
hanced neovascularization, including angiogenesis and arteriogenesis,
to treat vascular diseases.
The injection system is another important consideration for cell-
based therapies. Polymeric microcapsules and microcarriers haveoffered new possibilities for therapeutic materials, including stem
cells. For tissue engineering and cell therapies, direct administration to
the target site increases localization, although it does not increase
engraftment and survival [29]. Injectable systems and implantation of
hydrogels are two well-established methods for localized treatment.
However, there are distinct differences between both systems with
respect to the treatment methods, which include direct injection for
the injectable system and simple surgery for the hydrogel implantation.
To verify these facts, we compared our injectable microgel system,
formed by electrospraying, to a hydrogel systemwith the same concen-
tration of OECs and growth factors, and injected/implanted both mate-
rials subcutaneously. In Fig. 8, it can be observed that the injectable
microgel system induced stronger effects for new vessel formation as
compared with PBS-injected group. For the hydrogel system, an in-
creased amount of blood vessels was observed, though the observed
blood vessels went around the injection site. We speculate that this
may be due to tissue damage that was induced by the hydrogel, which
could be caused by the release of a high concentration of CaCl2, which
wasused to cross-link the alginate structure, a lowoxygenpermeability,
or a physical hindrance of the injected bolus. In addition,mice that were
injected with the hydrogel demonstrated a 70% mortality rate, whereas
mice treated with our injectable RGD-alginate microgel system
demonstrated a 100% survival rate.
Moreover, the mice used in this study have a normal activated
immune response. Nevertheless, the result of enhanced neovasculariza-
tion using the RGD-alginate microgels containing OECs and growth
factors delineates that our encapsulation system may protect OECs
and angiogenic factors against a host immune response, indicating
that the injectable microgel system is safer, more convenient, and
more applicable in the clinical ﬁeld, when compared to a hydrogel
system. In contrast, an inﬂammatory response was observed near the
scar at the implantation site in hydrogel-treated mice (Fig. 8).
Taken together, enhanced neovascularization when using the RGD-
alginate microgels, containing OECs and VEGF/HGF growth factors
may be caused by the complementary function of OECs and growth fac-
tors in an immunologically and physically safe microgel environment.
CD
PBS OECs onlyMicrogel only
Microgel with OECs Microgel with OECs+Growth factors
X 400
X 400
OECs only Microgel with 
OECs
Microgel with OECs
+Growh factors
0
200
400
600
800
1000
1200
1400
B
lo
od
 v
es
se
l d
en
si
ty
 (#
/m
m2
)
Treatment groups
Fig. 7 (continued).
11P.-H. Kim et al. / Journal of Controlled Release 187 (2014) 1–13All of our data showed that, besides direct vasculogenesis by the OECs,
improved neovascularization of the ischemic tissues was achieved
through proangiogenic and proarteriogenic paracrine effects. These
results are consistent with those from other studies involving various
angiogenic proteins and EPCs [30–32].We also believe that the OECs re-
leased from themicrogelmay assist in the improved neovascularization,
although other experiments would be required to prove this. Yu et al's
research, which showed that human mesenchymal stem cells that
were encapsulated in a microgel were able to migrate through the
scaffold materials [33], support the possibility of our hypothesis. Taken
together, our RGD-alginate microgel system, in combination with
endothelial progenitor cells and VEGF/HGF growth factors, which wasgenerated by an electrospraying technique, may demonstrate a sub-
stantial therapeutic potential by treating vascular disease in a variety
of clinical applications. This can be achieved via locally injectable ad-
ministration while avoiding the negative side effects that are some-
times associated with this type of administration.
5. Conclusion
Current trends in the ﬁeld of cell therapy include strategies that
combine nanotechnology and biomedical treatment to increase the
therapeutic potency. The present study is the ﬁrst report focused on
the therapeutic effects of OECs and growth factors encapsulated within
A B
Fig. 8.A comparison of the injectable microgel system and the implanted hydrogel system showing the superiority of our system. The RGD-alginate microgels or -hydrogels, formed using
the same concentration of cells and growth factors,were subcutaneously injectedor transplanted, respectively. The remaining RGD-alginatemicrogels or -hydrogel aswell as the induction
of blood vessels at injection site were compared after skin incision. The yellow arrow depicts the remaining microgels and hydrogel.
12 P.-H. Kim et al. / Journal of Controlled Release 187 (2014) 1–13RGD-alginate microgels formed by electrospraying. The encapsulated
OECswere able to safely proliferate in a time-dependentmannerwithin
the microgel. The RGD-alginate microgels demonstrated the long-term
release of the encapsulated materials in vitro. When the OECs and
growth factors were combined into the RGD-alginate microgels, the
therapeutic potency to create new blood vessels was increased via
neovasculogenesis compared with the use of a single material. Our
injectable microgel systemwas shown to be superior to a hydrogel sys-
tem by showing no toxicity when inducing new blood vessel formation.
Furthermore, the injectable microgel system containing OECs and
growth factors may not only decrease the host immune response
against the injected materials, but can also allow for repeated adminis-
trations. Taken together, our results indicate that the cell-based encap-
sulation technique using RGD-conjugated alginate microgels may be
a promising strategy to improve the therapeutic efﬁcacy for the
delivery of therapeutic cells and angiogenic proteins.
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